Meta AnalysisID 3737
黄嘌呤氧化酶抑制剂用于改善慢性肾脏病患者的肾损害
CRD42017067881
To investigate whether xanthine oxidase inhibitors may ameliorate renal damage in individuals with manifested signs of chronic kidney disease (CKD). To assess the safety profile of these agents (risk of adverse effects)
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3737
- Evidence Id
- 12295
- Core Evidence Id
- 12295
- Source Meta Analysis Id
- 3698
- Herb2 Meta Analysis Id
- HBMA003698
- Crd Id
- CRD42017067881
- Title
- Xanthine oxidase inhibitors for improving renal damage in CKD patients
- Review Question
- To investigate whether xanthine oxidase inhibitors may ameliorate renal damage in individuals with manifested signs of chronic kidney disease (CKD). To assess the safety profile of these agents (risk of adverse effects) in this population.
- Study Type Included
- Any type of study could be included, except case reports or case series, reviews, editorials, letters, and studies not providing long-term data on the outcomes of interest.
- Condition Being Studied
- Chronic kidney disease (CKD) is a major public health problem as it is associated with elevated cardiovascular morbidity, mortality and hospitalizations.
- Participant
- Patients with CKD, which is defined according to the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines by the presence of a reduced glomerular filtration rate (GFR) <90 mL/min/1.73 m-squared or the persistence of urinary abnormalities, such as albuminuria, proteinuria or hematuria in subjects with a GFR =90 mL/min/1.73 m-squared.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion criteria: studies dealing with CKD individuals undergoing treatment with any xanthine-oxidase inhibitors (including but not limited to allopurinol, febuxostat or topiroxostat), providing information on the effects of these drugs on renal function/damage. Exclusion criteria; treatment with other drugs endowed with hypouricemic effects (e.g., losartan), or studies dealing with CKD patients on acute renal replacement therapy (e.g., acute dialysis or peritoneal dialysis). Studies where at least part of the population fulfilled the above criteria will be included in the review.
- Comparator Control
- Any type of comparator, including but not limited to placebo or standard care.
- Main Outcome
- End-stage kidney disease (ESKD), defined as the need for renal replacement therapy or kidney transplantation, or doubling of serum creatinine.
- Outcome Measure
- Additional Outcome
- Changes in serum creatinine, proteinuria, albuminuria, and renal function (creatinine clearance/eGFR). Risk of adverse events will also be assessed.
- Study Method
- Intervention, Systematic review
- Keyword
- Enzyme Inhibitors; Gout Suppressants; Humans; Kidney; Renal Insufficiency, Chronic; Xanthine Oxidase
- Contact
- Dr Bolignano [email protected]
- Organisational Affiliation
- CNR-IFC https://www.ifc.cnr.it/index.php/en/
- Funding Source
- None.
- Other Selection Criteria
- Final Publication
- https://www.ncbi.nlm.nih.gov/PubMed/29088122
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Italy
- Review Stage
- Review Completed published
- First Submission Date
- 2018-01-29
- Registration Date
- 2017-05-25
- Anticipated Start Date
- 2017-05-25
- Anticipated Completion Date
- 2017-07-31
- Title Cn
- 黄嘌呤氧化酶抑制剂用于改善慢性肾脏病患者的肾损害
- Title En
- Xanthine oxidase inhibitors for improving renal damage in CKD patients
- Bilingual Status
- complete